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Activin-A and activin-B, members of the TGF-β superfamily, are regulators of reproductive
functions, inﬂammation and wound healing. These dimeric molecules regulate various cellular
activities such as proliferation, migration and suvival. Malignant mesothelioma is an asbestos
exposure related tumor affecting mainly pleura and it usually has a dismal prognosis. Here, we
demonstrate that both activin-A and -B are abundantly expressed in mesothelioma tumor tissue
as well as in cultured primary and established mesothelioma cells. Migratory and invasive
mesothelioma cells were also found to have attenuated activation of the Smad2/3 pathway in
response to activins. Migration and invasive growth of the cells in three-dimentional matrix was
prevented by inhibition of activin activity using a soluble activin receptor 2B (sActR2B-Fc). This
was associated with decreased ERK activity. Furthermore, migration and invasive growth was
signiﬁcantly inhibited by blocking ERK phosphorylation. Mesothelioma tumors are locally
invasive and our results clearly suggest that acivins have a tumor-promoting function in
mesothelioma through increasing expression and switching from canonical Smad3 pathway to
non-canonical ERK pathway signaling. Blocking activin activity offers a new therapeutic approach
for inhibition of mesothelioma invasive growth.
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).lsevier Inc. This is an open access article under the CC BY-NC-ND license
4.0/).
ptor; ALK, activin receptor-like kinase; ERK, extracellular signal-regulated kinase; FST,
N-terminal kinase; TGF-β, transforming growth factor-β
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Table 1 – Mesothelioma patient characteristics.
Patient Type Location Age Gender
JP1 Epithelial Pleura 53 Male
JP2 Biphasic Pleura 71 Male
JP3 Epithelial Pleura 63 Male
JP4 Biphasic Peritoneum 72 Female
JP5 Epithelial Pleura 69 Female
JP6 Biphasic Pleura 71 Female
JP7 Epithelial Pleura 62 Male
JP8 Epithelial Pleura 63 Male
JP9 Epithelial Pleura 54 Male
JP10 Epithelial Pleura 75 Male
JP11 Epithelial Pleura 65 Male
JP12 Epithelial Pleura 60 Male
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Malignant mesothelioma is a rare but very aggressive tumor originat-
ing from mesothelial cells lining body cavities. Most commonly
mesothelioma affects pleura, sometimes peritoneum and very rarely
pericardium. Mesothelioma is usually related to previous asbestos
exposure and develops during a latency of 20–40 years [1]. The
incidence of mesothelioma is expected to increase worldwide in the
near future [2,3]. Late stage of the disease at the time of diagnosis as
well as only moderate effectiveness of current therapies lead to
negligible survival time of the patients after diagnosis. Novel potential
diagnostic markers for early detection and drug targets are needed for
mesothelioma.
Activins, members of the TGF-β superfamily of growth factors,
are known regulators of development and reproductive functions
[4]. Currently, activins, especially activin-A, are also recognized as
important regulators of immune responses, wound healing and
cancer [5]. Activins enhance cell proliferation and migration as well
as scar formation during wound healing [5]. Increased cell pro-
liferation and migration are also characteristics of cancer cells. In
addition, activins may also promote tumor progression indirectly
by altering the tumor microenvironment through regulation of
immune functions and angiogenesis. Whether activins promote or
inhibit carcinogenesis depends on the cell, tissue and cancer type
[5–7]. A recent study reports that activin-A promotes mesothe-
lioma cell growth and migration through regulation of cyclin D [8].
The genes INHBA and INHBB code for the activin β-subunits,
which form disulﬁde-linked functional dimers. Homodimeriza-
tion of the βA-subunits generates activin-A and βB-subunits form
activin-B [9]. The β-subunits can also heterodimerizise and form
activin-AB. The β-subunits heterodimerisize also with α-subunits
and form inhibins, which inhibit activin action by competing for
activin receptors. Activin signaling is also regulated by soluble
inhibitors follistatin (FST) and follistatin like-3 (FSTL3) [10], which
inhibit activin action by binding to activins and blocking associa-
tion with cell surface receptors [11].
Activins signal through activin type 1 and type 2 transmembrane
serine/threonine kinase receptors. Activin action is initiated when
activin binds to a type 2 activin receptor (ACVR2A or ACVR2B). This
binding leads to recruitment, phosphorylation and activation of type
1 activin receptor followed by phosphorylation and activation of
Smad proteins. Both activin-A and -B can activate the Smad2/3 path-
way through type 2 receptors and common type 1 receptor ActR1B
(activin like kinase-4, ALK-4) [12]. Activin-B can also activate Smad2/3
via ActR1C (ALK7) [13,14]. Furthermore, activin-B has been reported
to activate Smad1/5/8 through BMPR1A (ALK3) [15]. The receptors
that bind TGF-β-family members can also activate non-Smad proteins
[16]. Activin-A can induce ERK and p38 MAP kinase phosphorylation
[17], and activin-B has been reported to be able to phosphorylate
SAPK/JNK and to induce keratinocyte migration [18] and wound
healing [19]. Furthermore, activation of both JNK and ERK is required
for activin-B induced migration in bone marrow-derived mesenchy-
mal stem cells [20]. Activin-A and activin-B have partially overlapping
expression patterns but are functionally distinct [21].
In this study, we characterized activin-A and -B expression and
their receptors in mesothelioma tissue and in cultured primary and
established mesothelioma cells. We aimed to clarify the role of
Smad mediated and non-canonical activin signaling in mesothe-
lioma cell migration and invasion. We report here that activins areabundantly expressed in mesothelioma cells and that by blocking
activin activity the migration and invasive growth of mesothelioma
cells can be signiﬁcantly reduced. Furthermore, our results suggest
a new mechanism through which mesothelioma cells promote
migration and invasive growth: switching activin signaling from
canonical Smad3 pathway to non-canonical ERK pathway signaling.Materials and methods
Antibodies and growth factors
Mouse monoclonal antibodies against human activin-A (mAb 18/
26A) and activin-B (mAb 12/9A for IHC, 46A/F for Western blotting)
subunits and follistatin (mAb 4/73C for IHC, 4/208 for Western
blotting) were generated by AnshLabs LLC (Webster, TX). Rabbit
monoclonal p-ERK1/2 and mouse monoclonal ERK1 were from Cell
Signaling (Danvers, MA). Human recombinant activins were from
R&D Systems (Gaithersburg, MD) and used at 25 ng/ml. The recom-
binant fusion protein contaning the ectodomain of human ActR2B
(sActR2B-Fc) or anti-Müllerian hormone receptor (sAMHR2-Fc) fused
to the Fc domain of human IgG1 was produced as described
previously [22] and used at 650 ng/ml (2D) or 10 mg/ml (3D). Soluble
receptors sequester ligands and inhibit their binding to cell surface
receptors. MAP kinase kinase (MEK) inhibitor PD98059 was from
Calbiochem (Merck, Darmstadt, Germany) and used at 30 μM.
Patients and tissues specimen
A statement for the use of human tissue and pleural effusion
materials was approved by the Ethics Committee of the Helsinki
University Hospital, Helsinki, Finland (permit number 308/13/
0301/2010). All patients gave written informed consent to parti-
cipate in the study. Tissue biopsies and pleural effusion samples
were obtained from patients who were undergoing diagnostic
procedures and who had a clinical and/or radiological suspicion of
malignant mesothelioma. All patients included in the study
(n¼12) were later diagnosed to have mesothelioma conﬁrmed
by a biopsy from the tumor tissue (Table 1).
Immunohistochemical staining
Parafﬁn-embedded tissue from mesothelioma tumor samples were
processed and stained using the Novolink Polymer Detection System
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visualized by diaminobenzidine (DAB, Vector Laboratories) has been
reported previously [23]. For follistatin staining, the formalin-ﬁxed
parafﬁn embedded specimens were stained on Leica BOND-MAX
fully automated staining system as deﬁned in the manufacturer's
staining protocol [with the Leica Bond Polymer Reﬁne Detection-kit,
Bond Epitope Retrievel Solution 2, 20 min, R.T.U. Normal Horse
serum 2.5% (Vector Laboratories, Burlingame, CA) blocking]. Images
of IHC sections were captured with Nikon DS-Fi1 (Nikon, Amster-
dam, Netherlands).Cell culture
Immortalized normal mesothelial cells (Met5A) [24] and
mesothelioma cell lines (211H, H28, H2452, H2052) were from
ATCC. Primary mesothelioma cells (JP cells) were obtained from
pleural effusion samples from malignant mesothelioma patients
as described in Tamminen et al. [25]. Cells were cultured in RPMI-
1640 media (Sigma, St Luis, MO) supplemented with 10% fetal
bovine serum (Gibco, Paisley, UK) and antibiotics (Gibco, Grand
Island NY). Cells were stimulated with activin-A (25 ng/ml),
activin-B (25 ng/ml) or sActR2B-Fc (650 ng/ml) for 90 min under
serum-free conditions.Transient transfection and luciferase assay
Cells to be transfected were seeded in 96-well plates. The cells
were co-transfected with promoter constructs (CAGA)12-luc
(Smad3 responsive), ARE-luc/Fast-1 (Smad2 responsive) or
(Bre)2-luc (Smad1/5 responsive), kindly provided by Dr. Peter
ten Dijke (Leiden University Medical Center, the Netherlands),
together with pRL-TK (Renilla Luciferase control, Promega, Madi-
son, WI) plasmid using Fugene HD transfection reagent (Roche,
Basel, Switzerland). The transfection, cell lysis and the measure-
ment of the luciferase activity were performed as described in
Tamminen et al. [26]. The cells were stimulated for 24 h under
serum-free conditions where indicated.RNA isolation and quantitative RT-PCR
Total cellular RNA was isolated using RNeasy Mini kit (Qiagen,
Hilden, Germany) and reverse transcribed to cDNA using iScript
cDNA synthesis Kit (Bio-Rad, Hercules, CA) according to the
manufacturer's instructions. The quantitative RT-PCR was per-
formed as previously described [26].Fig. 1 – Activins are abundantly expressed in mesothelioma tumor
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Cells were lysed and protein concentrations were measured as
described earlier [26]. Equal amounts of protein were separated by
SDS-PAGE using 4–20% gradient Tris–glycine gels (Bio-Rad). Con-
ditioned media from mesothelioma cell cultures were collected
during 2 days, concentrated using Amicon Ultra 10K centrifugal
ﬁlters (Millipore, Merck, Darmstadt, Germany) and separated by
SDS-PAGE. The transfer of the proteins to Protran nitrocellulose
membranes (Whatman, Springﬁeld Mill, UK),Western blotting and
ﬁnal detection of the proteins were performed as described
previously [26]. Relative band densities were quantiﬁed using
ImageJ software (National Institutes of Health, Bethesda, MA, USA).
Cell migration assays
The migratory capacity of the cell lines was analyzed using Incucyte
ZOOM 2013A kinetic live cell imaging system (Essen Bioscience,
Hertfordshire, UK) according to the manufacturer's instructions.
Brieﬂy, the cells were plated on 96-well plates and the next day a
wound was applied using a woundmaker (Essen Bioscience). The
media was replaced with serum-free media supplemented with
sActR2B-Fc where indicated. Two distinct pictures were taken of
each well every 2 h for 48 h. Data were analyzed with Incucyte
ZOOM 2013A software and the relative wound density was used as a
measure of the wound closure. Alternatively, cells were seeded on
12-well plates and wounds were made in conﬂuent monolayers
using a P200 pipette tip. The media was replaced with serum-free
media supplemented with DMSO, PD98059 or sActR2B-Fc where
indicated. Two pictures per well were taken after 0, 6, 24 and 48 h
using Nikon Eclipse TS 100 and Digital Sight DS-L2 (Nikon). The
wound density was quantiﬁed using Image ProPlus 7.0 software
(Media Cybernetics, Inc., Rockville, MD) and is shown as % area
occupied by cells relative to % wound area and has been normalized
to wound density data at the 0 h time point. The control treated
wound density has been set to one.
3D invasive growth assay
The lower Matrigel gel (BD Biosciences, San Jose, CA) was laid on
the bottom of the well on a 96-well plate and allowed to solidify at
37 1C for 45 min. Next, 3000–4000 cells per well were seeded and
allowed to attach for 1 h after which the media was carefully
removed and replaced with the top gel. Before seeding, the cells
were pre-treated with sActR2B-Fc, sAMHR2-Fc, DMSO or PD98059
for 15 min where indicated. The top gel was allowed to solidify for
30 min after which media was added. Inhibitors were also added to
Matrigel and cell culture media on top of the gel.tissue as well as in cultured mesothelioma cells. (A)
ing activin-A, activin-B or follistatin antibodies. See Table 2 for
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Data were analyzed using PASW Statistics 21 program for Windows
(SPSS, Chicago, IL). Statistical difference between two independentgroups was evaluated using nonparametric Mann–Whitney U-test.
Statistical difference between more than two independent groups
was evaluated using nonparametric Kruskal–Wallis test. A p-value
of less than 0.05 was considered statistically signiﬁcant.
Table 2 – Scoring of activin-A, activin-B and follistatin
immunoreactivity in mesothelioma patient samples.
Patient Activin-A Activin-B Follistatin
JP2 þþþ þþþ þþ
JP3 þ þ þþ
JP5 þþþ þþ þ
JP6 þþþ þ þþ
JP7 þþþ þþ þþ
JP8 þþþ þ þþ
JP9 þþþþ þþþ þþþ
JP10 þþ þ þþ
JP11 þþþþ þþ þ
JP12 þþþþ þþ þþ
Extent of staining (score): no staining (0), weak staining (þ), moderate
staining (þþ), strong staining (þþþ) and very strong staining (þþþþ).
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Activin-A and -B are highly expressed in malignant
mesothelioma
Activins are known regulators of inﬂammation and tissue repair
processes [5,27]. Activin expression has also been linked to
malignant and ﬁbrotic conditions [7]. To analyze the expression
of activin-A and -B in mesothelioma, tissue biopsies from patients
were stained with speciﬁc antibodies against inhibin βA and βB
subunits. Immunoreactivity for both activins was abundantly
detected in mesothelioma tumors (Fig. 1A). All tumor samples
(n¼10) were positive for both activins. In 8 out of 10 samples the
immunoreactivity of activin-A was stronger compared to the
immunoreactivity of activin-B (Table 2). The immunoreactivity
localized into the mesothelioma tumor cells, while the stroma
was mainly negative. Capillary endothelium in the stroma was
found positive. In addition, normal and reactive pleura showed
immunoreactivity for both activins (not shown). Tumor cells were
also positive for follistatin immunoreactivity, which was observed
in a more heterogeneous pattern (Table 2). In addition to tumor
cells, follistatin was detected in the stroma, endothelium and
strongly in normal and reactive pleura (not shown).
We have previously described isolation and culture of primary
mesothelioma cells from patients' pleural effusion samples [25]. The
cells retain gene expression characteristics of the tumor at early
passage cultures. The mRNA expression levels of activin-A (INHBA)
and -B (INHBB) in primary cells were analyzed using quantitative
RT-PCR. Met5A cells, immortalized but non-tumorigenic mesothelial
cells that were used as controls, expressed both activin-A and -B. The
levels of activin-A were about 10-fold higher than activin-B levels
(Fig. 1B). All primary mesothelioma cells expressed considerably
higher levels of activins when compared to Met5A cells (Fig. 1B).
Primary cells that overexpressed mainly activin-A were isolated from
a patient with biphasic mesothelioma (JP4), while the other primary
cells were from patients with epithelioid type mesothelioma. We also
analyzed activin expression levels in established mesothelioma cell
lines (211H, H2052, H28, H2452) and found that there was more
heterogeneity in the expression levels of activin subunits compared
to primary cells (Fig. 1C). In general, activin mRNA expression levels
were signiﬁcantly higher, especially in 211H and H2052 cell lines,
than in Met5A cells. Interestingly, similar to what was found in JP4primary cells we observed speciﬁc upregulation of the activin-A
subunit in the 211H cell line, which is also isolated from a patient
with biphasic mesothelioma. Secretion of activin subunits into the
culture media was analyzed by Western blot analysis and found to
correlate with the mRNA expression data (Fig. 1D).
Follistatin and follistatin like-3 (FSTL-3) are extracellular inhibitors
of TGF-β family growth factors. They can bind to all activins and
inhibit their biological functions [10]. The mRNA expression levels of
FST and FSTL3 in mesothelioma cells were analyzed next. In primary
mesothelioma cells FST expression levels were downregulated, in
some cells (JP1 and JP4) more clearly than in others. FSTL3 mRNA
expression levels were elevated in 3 out of 4 primary mesothelioma
cells (Fig. 1E). In the established mesothelioma cell lines FST and
FSTL3 expression levels showed more variability. FST levels were
downregulated in H28 and H2452 cell lines, while upregulated in
211H and H2052 cell lines (Fig. 1F). FSTL3 mRNA expression levels
tended to decrease, which is in contrast to what was observed in the
primary cells. Secretion of FST into the culture media was analyzed
by Western blot analysis and found to correlate with the mRNA
expression data (Fig. 1D).
ALK7 and ACVR2A are overexpressed in mesothelioma cells
The cells' sensitivity to activins and other TGF-β superfamily
growth factors is deﬁned by cell surface receptor expression and
the speciﬁcity of the signal is deﬁned by the type 1 receptor [12].
Both activin-A and -B activate Smad2/3 pathway through ALK4
[12]. In addition, activin-B can activate Smad2/3 pathway through
ALK7 [13,14] and Smad1/5/8 pathway through ALK3 [15]. The
activin receptor mRNA expression levels were analyzed using
quantitative RT-PCR. Met5A cells expressed activin type 1 recep-
tors ALK3 and ALK4 and very low levels of ALK7 (Fig. 2A). Overall,
ALK3 and ALK4 mRNA expression levels were not consistently
altered in primary mesothelioma cells or in established mesothe-
lioma cell lines (Fig. 2A and C). However, ALK7 receptor expres-
sion was highly increased in primary mesothelioma cells (Fig. 2B).
In addition, all the established mesothelioma cell lines showed
higher levels of ALK7 when compared to Met5A cells (Fig. 2D).
Met5A cells expressed both activin type 2 receptors ACVR2A
and ACVR2B. The levels of receptor 2B were about 3-fold higher
than receptor 2A expression levels (Fig. 2E and F). This is in
contrast to what was observed in all primary mesothelioma cells.
The 2A receptor expression levels increased signiﬁcantly, while
receptor 2B levels decreased (13-fold higher level of receptor 2A
compared to receptor 2B on average) (Fig. 2E), suggesting that
there is a switch in the predominant type 2 receptor in mesothe-
lioma cells. This was also noted in 3 out of 4 established
mesothelioma cell lines (Fig. 2F). The H28 cell line was the only
one showing elevated levels of both type 2 receptors.
Mesothelioma cells have altered Smad activation in
response to activins
Activin-A and -B induced Smad responses were studied in meso-
thelioma cells using transient transfection of Smad3 responsive
[(CAGA)12-luc], Smad2 responsive [ARE-luc] or Smad1/5 responsive
[(Bre)2-luc] promoter-luciferase constructs followed by overnight
stimulation by activin-A or -B (see “Materials and methods” section).
Basal Smad3 activity was somewhat higher in primary cells (JP5)
compared to established mesothelioma cell lines or Met5A cells
Fig. 2 – The expression of ACVR2A and ALK7 is increased in mesothelioma cells. The mRNA expression levels of activin type 1 (ALK3,
ALK4 and ALK7) and type 2 (ACVR2A and ACVR2B) receptors were analyzed in primary mesothelioma cells (A, B, E) and in
mesothelioma cell lines (C, D, F). The expression levels were normalized to the expression levels of TATA-binding protein and are
shown relative to the expression levels of ALK4 (A, C), ALK7 (B, D) or ACVR2A (E, F) in Met5A cells. Error bars represent standard
deviation (n¼2). *pr0.025 Kruskal–Wallis test.
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fold in activin-B treated Met5A cells (Fig. 3B). The H28 mesothelioma
cell line showed similar responses. In contrast, H2052 and 211H cell
lines as well as JP5 primary cells had strongly attenuated activin
induced Smad3 activation.
Basal Smad2 activity differed between the cells. Signiﬁcantly
lower basal Smad2 activity was observed in 211H and H2052 cells
(Fig. 3C). Both activins induced Smad2 activity in Met5A cells.
Induction of activity was also observed in 211H cells, whereas
H2052 and H28 cells showed only a moderate 2-fold increase in
Smad2 activity in response to activin-A and -B (Fig. 3D). In JP5
primary cells activins failed to induce Smad2 activity.A tendency towards higher basal Smad1/5 activity levels were
noted in JP5 primary cells as well as in 211H and H2052 cells
compared to Met5A cells (Fig. 3E). H28 cell line showed signiﬁ-
cantly increased basal level Smad1/5 activity. Interestingly,
activin-B increased Smad1/5 activity in this particular cell line,
but not in any other cells tested (Fig. 3F).
Mesothelioma cells differ in migratory capacity
To analyze the migratory capacity of established mesothelioma cell
lines, a scratch-wound assay was performed. Cell migration was
monitored using a live-cell imaging system (see “Materials and
Fig. 3 – Activin induced Smad3 activation is attenuated in mesothelioma cells. Met5A and mesothelioma cells were transfected with
Smad3 (A, B), Smad2 (C, D) or Smad1/5 (E, F) responsive promoters and stimulated overnight with activin-A or -B. Promoter activity is
shown relative to the level in Met5A cells. (A) Basal Smad3 activity was somewhat elevated in primary mesothelioma cells (JP5, n¼2).
(B) Activin induced Smad3 activation was dramatically decreased in primary mesothelioma cells and in 211H and H2052 cell lines
(n¼2). (C) Basal Smad2 activity was downregulated signiﬁcantly in 211H and H2052 mesothelioma cells [**p¼0.007 Kruskal–Wallis
test comparing all samples; *p¼0.008 Mann–Whitney test comparing two groups (Met5A vs. 211H and Met5A vs. H2052) (nZ3)]. (D)
Activin-A and -B induced robust Smad2 activation in Met5A and 211H cells whereas other cells showed attenuated Smad2 response
(nZ2). (E) Basal Smad1/5 activity was signiﬁcantly increased in H28 cells and slightly increased in other mesothelioma cells
[**p¼0.006 Kruskal–Wallis test (nZ2); *p¼0.007 Mann–Whitney test comparing two groups (Met5A vs. H28) (nZ3)]. (F) Activin-B
induced Smad1/5 activation only in H28 cell line (nZ3). Error bars represent standard deviation.
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Fig. 4 – Inhibition of activin activity reduces mesothelioma cell migration. Cell migration was analyzed using a scratch-wound
assay and monitored by 48-h live cell imaging (A–C) or imaging at 0, 6, 24 and 48 h time points (D, E). The results are presented as
relative wound density. H2052 and 211H mesothelioma cells were found to rapidly close the wound. Inhibition of activin signaling
using a soluble type 2 receptor (sActR2B-Fc) delayed wound closure in 211H cells. Error bars represent standard deviation (n¼2).
(C) Representative pictures of 211H cells at the 24 h time point are shown. (D, E) Representative pictures of JP5 primary
mesothelioma cell scratch-wound assay. Inhibition of activin signaling (by sActR2B-Fc) delayed wound closure in primary cells
[p¼0.1 Mann–Whitney test, (n¼3)]. Error bars represent standard deviation.
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were observed (Fig. 4A). H2052 and 211H cells migrated efﬁciently
to close the wound. These two cell lines exhibited increased mRNA
and protein expression of activin-A as well as altered Smad3
signaling responses. H2452 cells were less migratory and H28 cells
were able to close the wound only after extended periods of time
(Fig. 4A). Migration of 211H cells reduced with addition of a soluble
activin inhibitor (sActR2B-Fc), suggesting that endogenous activins
contribute to 211H mesothelioma cell migration (Fig. 4B and C). The
migratory capacity of JP5 primary cells was measured using a
scratch-wound assay and imaging at 0, 6, 24 and 48 h time points.
JP5 cells were also found to migrate rapidly. Treatment with the
activin inhibitor sActR2B-Fc clearly delayed wound closure (Fig. 4D
and E). Similar to what was observed in 211H cells the inhibitionwas
clearly detectable at 24 h (Fig. 4D) and was sustained at 48 h, whensActR2B-Fc treated wounds were approximately half as dense as the
untreated control wounds (Fig. 4E).
Migratory mesothelioma cells also show invasive growth
in 3D
To analyze the invasive growth of mesothelioma cell lines, they
were seeded into 3D matrices and monitored for 36 h (see
“Materials and methods” section). The highly migratory cell lines
211H and H2052 were able to form irregular shaped spheroids and
invade through the Matrigel forming a network of sprouts (Fig. 5A),
whereas H28 and H2452 cells were unable to do this. Next we
analyzed whether activin signals contribute to invasive growth. The
cells were pretreated with sActR2B-Fc, which binds and inhibits
the action of both activin-A and -B, before they were seeded into
Fig. 5 – Invasive growth of mesothelioma cells was analyzed in three-dimensional matrix. (A) 211H and H2052 cells, but not H28
and H2452 cells, embedded in Matrigel were able to form irregular shaped spheroids as well as invade and sprout through the
surrounding matrix. (B-D) Inhibition of activin signaling (by sActR2B-Fc) prevented invasive growth of 211H, H2052 and JP5
primary cells. Soluble anti-Müllerian hormone receptor (sAMHR2-Fc) was used as a negative control and had no effect on invasive
growth. Representative pictures are shown. Original magniﬁcation 100 . Inset: high magniﬁcation picture.
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the invasive growth of 211H and H2052 mesothelioma cell lines
(Fig. 5B and C) as well as JP5 primary cells (Fig. 5D). Addition of a
soluble anti-Müllerian hormone receptor (sAMHR2-Fc), which was
used as a control treatment, had no impact on invasive growth
(Fig. 5B). These results suggest that activins contribute to the
invasive growth properties of mesothelioma cells.ERK activity contributes to mesothelioma cell migration
and invasive growth
Activins can also induce non-canonical signaling pathways. These
include the ERK and JNK MAP kinase pathways, which have been
shown to contribute to cell migration [17,20]. ERK phospho-
rylation, i.e., activation was analyzed by Western blotting after
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control cells activins did not induce ERK phosphorylation, instead,
pERK levels seemed to decrease. In contrast, in H2052 and JP5
primary cells activins induced robust ERK phosphorylation
(Fig. 6A). Activin-A seemed to induce a stronger response than
activin-B. To determine whether endogenous activins support
ERK activation, mesothelioma cells were treated with the soluble
activin inhibitor sActR2B-Fc. In all migratory and invasive
mesothelioma cells (211H, H2052 and JP5) sActR2B-Fc treatment
reduced ERK phosphorylation levels signiﬁcantly (Fig. 6B and C).
Due to a limited possibility to do experiments with early passage
primary cells (n¼2), the decrease in JP5 cells did not, however,
reach statistical signiﬁcance. In the other cell lines (Met5A, H28
or H2452) treatment with sActR2B-Fc did not lead to similar
reduction in ERK phosphorylation (not shown). No signiﬁcant
changes in JNK1/2 phosphorylation in response to activin stimu-
lation were detected (not shown).
To analyze the involvement of ERK activity in mesothelioma cell
migration a scratch-wound assay was performed in the presence
or absence of an inhibitor of the upstream kinase MEK (PD98059).
In JP5 primary cells as well as in 211H and H2052 cells wound
closure was considerably delayed by the MEK inhibitor (Fig. 6D
and E). Compared to DMSO treated control cells, in MEK inhibitor
treated 211H and JP5 primary cells a signiﬁcantly delayed wound
closure was observed at 48 h. In H2052 cells the delay in wound
closure was signiﬁcant already at 6 h when the wounds were
approximately half as dense as the control wounds (Fig. 6E).
Unlike in the DMSO treated control, H2052 wounds remained
open in the presence of the MEK inhibitor at 24 h (Fig. 6D).
Activin-A increased H2052 cell migration. After six hours, the
wounds were approximately twice as dense as the control
wounds (Fig. 6F and G). Treatment with the MEK inhibitor
signiﬁcantly delayed the wound closure also in activin-A stimu-
lated cells (Fig. 6F and G).
The contribution of ERK pathway activity to the invasive growth
of mesothelioma cells was analyzed next. Cells were pretreated
with the MEK inhibitor or DMSO, after which the cells were
seeded into 3D matrices. Inhibition of ERK pathway activity
signiﬁcantly inhibited invasive growth of 211H and JP5 primary
cells (Fig. 6H). This was similar to what was observed with
sActR2B-Fc. In addition, H2052 cells showed a similar trend of
decreased ability for invasive growth (not shown). However, this
observation was not so clear due to the sensitivity of H2052 cells
to DMSO control treatment in a three-dimensional setting. Taken
together, our data suggest that inhibition of ERK activity efﬁ-
ciently prevents mesothelioma cell invasive growth.Discussion
TGF-β family growth factors have an important role during develop-
ment and adult tissue homeostasis. There is also ample evidence
linking aberrant growth factor activity to cancer progression [28].
TGF-β activity has been linked to mesothelioma, but the role of
activins is less well understood. There is one study showing over-
expression of activin-A in mesothelioma and suggesting a function in
the regulation of mesothelioma cell proliferation [8]. Here, we provide
evidence that activin-A and activin-B are important regulators of
mesothelioma cell migration and invasive growth properties. By
blocking activin activity using a soluble inhibitor, we can efﬁcientlyinhibit invasive growth in a three-dimensional culture system.
Mesothelioma cells showed a clear difference in signaling responses
to activins, which may be a key mechanism for the invasive growth
inducing activity. Similar to what has been described for TGF-β
[29,30], we speculate that increased activin production and altered
signaling responses in malignant cells mediate a switch in their
function from a tumor suppressor to a tumor promoter. Interestingly,
suppression of Smad activity and concomitant increase in ERK
activation has been suggested to mediate the switch in TGF-β function
during tumor progression [31].
All mesothelioma tumors showed consistently high immunoreac-
tivity for activin-A, which is in agreement with a previous report [8].
In addition, activin-B immunoreactivity was observed in all tumors.
Immunoreactivity for the activin inhibitor follistatin, on the other
hand, was more variable and not consistently altered in tumors. We
have analyzed primary mesothelioma tumor cells isolated from
pleural effusion samples [25] and found very consistent changes in
the activin signaling pathway. Established mesothelioma cell lines
showed clearly more heterogeneity, which suggests that it is
important to use cell lines with similar characteristics as the primary
tumors in mechanistic studies. Primary mesothelioma cells and
migratory and invasive mesothelioma cell lines showed increased
expression of activin-A, activin-B, ALK7 and ACVR2A, as well as ERK
activation and attenuated Smad2/3 signaling responses. These
alterations were clearly associated with a migratory and invasive
growth phenotype, which could be blocked using a soluble activin
inhibitor (sActR2B-Fc) or MEK inhibitor.
Activins can use different receptor heterodimers to mediate
signaling. We found a signiﬁcant upregulation of ALK7 receptor in
mesothelioma. As ALK7 is an activin-B preferring receptor coex-
pression of ACVR2 and ALK7 should provide sensitivity to activin-
B. In addition to activin-B also Nodal is a ligand for ALK7 [32].
Nodal is a developmental morphogen, which has been linked to
cancer stem cell phenotype, epithelial-to-mesenchymal transition
and invasion in other malignancies [33]. The possible role of
Nodal in mesothelioma remains to be elucidated. Another inter-
esting ﬁnding was a switch from a predominant expression of
type 2 receptor ACVR2B to ACVR2A. This may lead to changes in
activin mediated intracellular signaling and function as an adap-
tation mechanism required for cells to escape growth/invasion
limiting actions of activins. Since activin type 2 receptors are
involved in a variety of receptor signaling complexes, the switch
of the predominantly expressed receptor may also alter responses
to other TGF-β family ligands. We observed a clear association of
type 2 receptor expression proﬁle with loss of Smad3 responsive-
ness and migratory and invasive phenotype. H28 mesothelioma
cells did not show this receptor swich, were sensitive to Smad3
activation and did not show high migratory or invasive growth
phenotype. H28 cells have been shown to lack β-catenin [34],
which is not a typical feature of mesothelioma [35]. This suggests
that H28 is a unique mesothelioma cell line.
Activins can induce inhibition of proliferation and apoptosis [5].
Cancer cells can avoid these suppressive functions through various
mechanisms. Loss of the CDKN2A/ARF locus is the most common
genetic alteration in mesothelioma and leads to inactivation of the
p16INK4a tumor suppressor gene [36]. This may also reduce activin
induced apoptotic responses [37]. Smad-mediated signaling is also
crucial for activin induced growth arrest [38]. We have shown here a
clear transformation in activin induced intracellular signaling cas-
cades in mesothelioma cells. Smad3 activation, measured using a
E X P E R I M E N T A L C E L L R E S E A R C H 3 3 2 ( 2 0 1 5 ) 1 0 2 – 1 1 5112promoter assay, was almost lost in migratory and invasive mesothe-
lioma cells, while Smad2 activation was partially retained in some
cell lines. In addition, TGF-βwas still able to induce Smad3 activation
(our unpublished data), suggesting an activin speciﬁc loss of
responsiveness. Higher follistatin expression levels in established
mesothelioma cell lines could not explain the loss of responsiveness,
since activins induced a robust ERK activation in H2052 cells.Furthermore, JP5 primary cells had low levels of follistatin expres-
sion but attenuated Smad3 activation. We have previously shown
high P-Smad2 immunoreactivity in mesothelioma tumor samples
[39], but P-Smad3 levels in vivo have not been speciﬁcally analyzed
and remain to be determined.
Previously it has been observed that activin-B induces skin
wound re-epithelialization through Smad3-independent mechan-
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in Smad3 knockout mice [41]. The ERK pathway has been found
important for activin induced epithelial wound healing [40]. The
migratory and invasive growth phenotype in mesothelioma cells
was also clearly associated with activin induced ERK activity, since
inhibition of both activin-A and -B by using a soluble type 2
receptor reduced levels of ERK phosphorylation and migration and
invasive growth in 3D matrix. Similar effects were observed when
ERK phosphorylation was blocked with an inhibitor of the upstream
kinase MEK. ERK is one of the well-known activators of cyclin D
[42]. Our results are in agreement with a report by Hoda et al. [8]
suggesting that activin-A can also function through cyclin D in
mesothelioma. The ERK pathway is involved in the regulation of cell
cycle progression, apoptosis and differentiation. It is also commonly
activated in tumors [43]. ERK is known to be highly activated in
mesothelioma [44] and central to mesothelioma cell migration,
proliferation as well as tumor development and chemoresistance
[45]. In addition to TGF-β family ligands, receptor tyrosine kinases
can contribute to ERK pathway activity in mesothelioma cells.
Fibroblast growth factor receptor (FGFR)1 was recently found
upregulated in mesothelioma cells and in patient samples [46].
Inhibition of growth caused by FGFR inhibition was associated with
downregulation of basal ERK activity [46].
The exact molecular mechanism of the swich from Smad3
signaling to ERK pathway signaling in activin responsive mesothe-
lioma cells remains to be elucidated. Changes in activin type 2
receptor expression proﬁle may contribute to this switch. Down-
regulation of TGF-β type 2 receptor has been implicated in the loss
of responsiveness to the anti-proliferative effects of TGF-β in lung
cancer cells [47]. In addition to changes in receptor expression, it
has been suggested that a speciﬁc isoform of PP2A is differentially
recruited to TGF-β type 1 receptor in normal and malignant cells
leading to differential activation of ERK [31]. Under hypoxic
conditions PP2A can dephosphorylate Smad3 without affecting
Smad2 [48]. Similar mechanisms may play a role in the observed
alterations in activin responses.
Mesotheliomas are characterized with aggressive and locally
invasive phenotypes. Understanding of the mechanisms that the
tumor invasion is vital for the development of treatment strategies.
Cancer cells and the tumor microenvironment both contribute to the
invasive phenotype of the tumors. We have shown here that
mesothelioma cells produce activin-A and -B, which both contribute
to the invasive and migratory phenotype of the cancer cells. High
expression levels of activins are associated with attenuation of the
canonical Smad3 signaling and increase in non-canonical ERK
signaling responses. Similar changes in the signaling pathways haveFig. 6 – ERK activity is essential for activin induced mesothelioma
with activin-A or -B for 90 min and analyzed for ERK phosphoryla
were treated with sActR2B-Fc (90 min) to inhibit activin signaling,
Mann–Whitney test (n¼4); JP5 primary cells (n¼2)]. (D) Represen
scratch-wound assay are shown. (E) Compared to DMSO treated con
closure. H2052 cell wound density was analyzed at the 6 h time po
the 48 h time point [*p¼0.029 Mann–Whitney test (n¼4); JP5 prim
(F) Representative pictures of H2052 scratch wound assay are show
point. The wound density in activin-A stimulated cells was twice a
inhibitor (PD98059) signiﬁcantly delayed wound closure in activin
The effect of inhibition of ERK activity to mesothelioma cell invasi
MEK-inhibitor (PD98059). PD98059 prevented invasive growth of 2been associated with the function of TGF-β as a tumor promoter in
cancer cells [31]. In conclusion, inhibition of activin or ERK activity, or
both, represents a therapeutic approach for inhibition of invasive
mesothelioma tumors. Novel inhibitors of activin signaling are under
development for clinical use, which makes activins a plausible target
for adjunctive therapy in mesothelioma.Acknowledgments
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